Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?

@article{Dunlop2015SchizophreniaDD,
  title={Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?},
  author={John Dunlop and Nicholas J. Brandon},
  journal={Journal of psychopharmacology},
  year={2015},
  volume={29 2},
  pages={230-8}
}
Current therapeutics for schizophrenia, the typical and atypical antipsychotic class of drugs, derive their therapeutic benefit predominantly by antagonism of the dopamine D2 receptor subtype and have robust clinical benefit on positive symptoms of the disease with limited to no impact on negative symptoms and cognitive impairment. Driven by these therapeutic limitations of current treatments and the recognition that transmitter systems beyond the dopaminergic system in particular glutamatergic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
25 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…